CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：STYK1 as a targetable vulnerability enhances the efficacy of anti-PD-L1 therapy in pancreatic cancer.
STYK1 as a targetable vulnerability enhances the efficacy of anti-PD-L1 therapy in pancreatic cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
STYK1 是 PDAC 免疫治疗反应的潜在预测生物标志物，因其通过 CCL20 调控 T 细胞浸润，且不依赖于 PD-1/PD-L1 通路，这可能提供一种潜在增强免疫治疗疗效的策略，尚待机制确认。
胰腺导管腺癌（PDAC）是一种高度致命的恶性肿瘤，治疗选择有限。免疫治疗虽然在多种肿瘤中有效，但由于免疫耐受，在PDAC中疗效有限。因此，寻找新的靶点以增强免疫治疗反应至关重要。
本研究利用生物信息学分析和公共数据库数据，确定STYK1为潜在的PDAC生物标志物。我们分析了STYK1在PDAC组织中的表达、其与患者预后和免疫细胞浸润的联系。体外实验评估了STYK1敲低对PDAC细胞增殖、迁移和侵袭的影响。对79例PDAC组织样本进行了免疫组化分析，以评估CD8 + T细胞浸润。体内研究检查了STYK1敲低对肿瘤生长、T细胞浸润和激活的影响，尤其是与抗PD-L1抗体联合时。我们还研究了STYK1调控T细胞浸润的分子机制，重点关注其与CCL20的关联及其在PD-1/PD-L1通路之外的作用。
PDAC组织中STYK1表达升高与不良预后和CD8+ T细胞浸润减少相关。体外实验中，敲低STYK1可抑制PDAC细胞增殖、迁移和侵袭。体内实验中，敲低STYK1可减缓肿瘤生长，并且与抗PD-L1抗体治疗联合使用时，可显著增强T细胞浸润和活化，而不影响PD-L1表达。STYK1通过CCL20调控T细胞浸润，且不依赖于PD-1/PD-L1信号通路。
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with limited treatment options. Immunotherapy, though effective in various tumors, has limited efficacy in PDAC due to immune tolerance. Thus, identifying new targets to enhance immunotherapy response is crucial.
This study used bioinformatics analysis and public database data to identify STYK1 as a potential PDAC biomarker. We analyzed STYK1 expression in PDAC tissues, its link to patient prognosis and immune cell infiltration. In vitro experiments assessed the impact of STYK1 knockdown on PDAC cell proliferation, migration, and invasion. Immunohistochemical analysis was performed on 79 PDAC tissue samples to evaluate CD8 + T cell infiltration. In vivo studies examined the effects of STYK1 knockdown on tumor growth, T cell infiltration and activation, especially with anti-PD-L1 antibodies. We also investigated the molecular mechanisms of STYK1's regulation of T cell infiltration, focusing on its association with CCL20 and its role beyond the PD-1/PD-L1 pathway.
Elevated STYK1 expression in PDAC tissue is associated with poor prognosis and reduced CD8 + T cell infiltration. STYK1 knockdown inhibits PDAC cell proliferation, migration, and invasion in vitro. In vivo, it decreases tumor growth and, when combined with anti-PD-L1 antibody treatment, significantly enhances T cell infiltration and activation without affecting PD-L1 expression. STYK1 regulates T cell infiltration via CCL20, independently of the PD-1/PD-L1 signaling pathway.
STYK1 is a potential predictive biomarker for immunotherapy response in PDAC, as its regulation of T cell infiltration via CCL20, independent of the PD-1/PD-L1 pathway, may provide a strategy to potentially augment immunotherapy efficacy, pending mechanistic confirmation.
MEMBER ACCOUNT
登录成功会直接打开下一页。
